Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session on Thoracic cancers

377O - A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer


21 Nov 2020


Proffered paper session on Thoracic cancers


Tumour Site

Small Cell Lung Cancer


Xinghao Ai


Annals of Oncology (2020) 31 (suppl_6): S1386-S1406. 10.1016/annonc/annonc367


X. Ai1, Y. Pan2, J. Shi3, N. Yang4, C. Liu5, J. Zhou6, X. Zhang7, X. Dong8, J. He9, X. Li10, G. Chen11, X. Li12, H. Zhang13, W. Liao14, Y. Zhang15, Z. Ma16, B. Zhang17, D. Zhang17, S. Lu1

Author affiliations

  • 1 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 200030 - Shanghai/CN
  • 2 Department Of Chemotherapy, Anhui Provincial Hospital, 230001 - Hefei/CN
  • 3 Department Of Medical Oncology, Linyi Cancer Hospital, Linyi/CN
  • 4 Lung & Gastrointestinal Oncology Department, Hunan Cancer Hospital, 410006 - Changsha/CN
  • 5 Department Of Pulmonary Medicine, Cancer Hospital Affiliated to Xinjiang Medical University, 830011 - Ürümqi/CN
  • 6 Department Of Respiratory Medicine, First Affiliated Hospital, Zhejiang University, 310003 - Hangzhou/CN
  • 7 Department Of Medical Oncology, Nantong Tumor Hospital, 226300 - Nantong/CN
  • 8 Cancer Center, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 - Wuhan/CN
  • 9 Department Of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, 510120 - Guangzhou/CN
  • 10 Department Of Thoracic Medicine, Liaoning Cancer Hospital & Institute, 110042 - Shenyang/CN
  • 11 Department Of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin/CN
  • 12 Department Of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN
  • 13 Department Of Oncology, Tangdu Hospital, Xi'an/CN
  • 14 Department Of Oncology, Nanfang Hospital, Guangzhou/CN
  • 15 Department Of Thoracic Medial Oncology, Zhejiang cancer hospital, Hangzhou/CN
  • 16 Department Of Medicine Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou/CN
  • 17 R&d Department, Zai Lab (Shanghai) Co., Ltd, Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 377O


Niraparib is a highly selective PARP-1/2 inhibitor approved by FDA for the maintenance therapy of ovarian cancer. It also showed promising activity as maintenance treatment in platinum sensitive SCLC PDX models. ZL-2306-005 is a randomized, double-blind, multicenter phase Ⅲ study to evaluate the efficacy and safety of niraparib (nira) versus placebo (pla) as first line (1L) maintenance therapy in extensive-stage SCLC (ES-SCLC) patients.


Patients (pts) with ES-SCLC, ECOG PS 0 or 1, CR/PR after 4 cycles of 1L etoposide/cisplatin or etoposide/carboplatin were enrolled. Prophylactic cranial irradiation (PCI) was optional. Pts were randomized 2:1 to receive nira or pla once daily as maintenance therapy until progression or unacceptable toxicity. Nira started with 300mg QD for pts with baseline body weight ≥77 kg and platelet count ≥150,000/μL, otherwise 200 mg QD. Stratified factors were gender, LDH level and PCI history. The primary endpoints were PFS by blinded independent central review (BICR) and OS; the secondary endpoints were PFS by investigator, CFI, QoL, safety and tolerability.


From Jul 2017 to Feb 2020, 272 pts were screened in 34 sites, of whom 185 were randomized and dosed according to protocol, 125 in nira arm and 60 in pla arm. The study was early terminated due to landscape changed by immunotherapy in ES-SCLC. At the data cutoff: 20 Mar 2020, there were 167 pts discontinued from the treatment and 70 pts died. Median PFS (BICR) was 1.54 m (1.41, 2.69) in nira arm and 1.36 m (1.31, 1.48) in pla arm (HR 0.66; 95% CI [0.46, 0.95]; p= 0.0242). Median OS was 9.92 m (9.33, 13.54) in nira arm and 11.43 m (9.53, NE) in pla arm (HR 1.03; 95% CI [0.42, 1.73]; p = 0.9052). Grade≥3 treatment-related AEs (TEAEs) was 34.4% in nira arm vs. 25% in pla arm. No patient had a TEAE leading to death.


Niraparib has modest improvement in PFS compared to placebo in 1L ES-SCLC maintenance with manageable and tolerated safety profile. OS benefit was not observed based on immature data. The value of adding niraparib to immunotherapy needs further investigation.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Zai Lab.


Zai Lab. Shanghai Science and Technology Commission (18DZ1910700).


B. Zhang, D. Zhang: Full/Part-time employment: Zai Lab. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.